1093975-41-7

Upstream product

• 68359-57-9 4-fluoro-3-phenoxybenzaldehyde 
• 1056991-19-5 2-azido-N-cyclohexyl-N-phenylacetamide 
• 1093980-60-9 1-(4-ethynyl-2-phenoxyphenyl)-4-methyl-1H-imidazole 
• 128495-46-5 4-fluoro-3-methoxybenzaldehyde 
• 100721-33-3 2-chloro-N-cyclohexyl-N-phenylacetamide 
• 1821-36-9 N-phenyl-2-cyclohexylamine 
• 1093980-57-4 1-(4-ethynyl-2-methoxyphenyl-4-methyl-1H-imidazole) 
• 870837-18-6 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde 

Relevant academic research and scientific papers

Triazoloamides as potent γ-secretase modulators with reduced hERG liability

Synthesis and SAR studies of novel aryl triazoles as gamma secretase modulators (GSMs) are presented in this communication. Starting from our aryl triazole leads, optimization studies were continued and the series progressed towards novel amides and lactams. Triazole 57 was identified as the most potent analog in this series, displaying single-digit nanomolar Aβ42 IC 50 in cell-based assays and reduced affinity for the hERG channel.

TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS

Compounds of formula I: Selectively attenuate production of Aβ(1-42) and hence find use in treatment or prevention of diseases associated with deposition of Aβ in the brain, in particular Alzheimer's disease.